Sumeer Tah
Sleep Medicine · Athens, GANPI 1114421682
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,203 of the $4,445 with a category attached, or 72.1%. 32 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 24.8% of the total. 2025 is the largest year on record at $2,299, more than ten times the $112 reported in 2021.
Across 150 payments — averaging $29.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- Harmony Biosciences LLC$478
- AstraZeneca$322
- Merck$241
- Boehringer Ingelheim$232
- Avadel CNS Pharmaceuticals, LLC$230
- plus $2K from 26 others
What the payments were for
- Consulting fees$2004%
- Travel & lodging$81718%
- Food & beverage$3,20372%
- Education$2245%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 15 | $1,104 |
| Harmony Biosciences LLC | 12 | $478 |
| AstraZeneca | 19 | $322 |
| Merck | 10 | $241 |
| Boehringer Ingelheim | 9 | $232 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $230 |
| Actelion Pharmaceuticals US, Inc. | 11 | $205 |
| Jazz Pharmaceuticals Inc. | 3 | $186 |
| GSK | 10 | $182 |
| Regeneron Healthcare Solutions, Inc. | 5 | $139 |
| Grifols USA, LLC | 6 | $137 |
| Sanofi | 5 | $128 |
| Mylan Specialty L.p. | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Fisher & Paykel Healthcare Inc | 2 | $73 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Insmed, Inc. | 3 | $60 |
| AbbVie | 4 | $59 |
| Bayer | 3 | $52 |
| Amgen | 3 | $51 |
| Lilly USA, LLC | 3 | $50 |
| Baxter Healthcare | 2 | $43 |
| Noctrix Health, Inc. | 1 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Verona Pharma, Inc. | 1 | $24 |
| Liquidia Technologies, Inc. | 1 | $24 |
| Inogen, Inc. | 2 | $23 |
| Philips North America LLC | 1 | $23 |
| United Therapeutics Corporation | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Resmed Corp | 1 | $20 |
| Shionogi Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,445 in reported general payments places this provider in the 75th percentile of 50 sleep medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 26 | $13,726 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,421 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,212 |
| Modafinil | 14 | $3,680 |
| DayvigoLemborexant | 11 | $3,653 |
| Gabapentin | 102 | $701 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $602 |
| Doxepin Hcl | 12 | $432 |
| Mirtazapine | 18 | $180 |
| Fluticasone Propionate | 18 | $169 |
| Hydroxyzine Hcl | 16 | $138 |
| Trazodone Hcl | 36 | $130 |
| Clonazepam | 18 | $113 |
| Ropinirole Hcl | 11 | $103 |
| Pregabalin | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $182 | $17,63328 claims |
| MerckBelsomra | $241 | $13,72626 claims |
| Eisai Inc.Dayvigo | $22 | $3,65311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 sleep medicine providers in Georgia.
Other sleep medicine in Athens
- Charles MixsonAthens$2K
- Deepak DasAthens$1K
- Murad AssaadAtlanta$139K
- Nancy CollopAtlanta$28K
- Scott LeibowitzAtlanta$22K
- Anuj ChandraTrenton$20K
- Chantale BransonAtlanta$17K
- Melissa RhodesCartersville$14K
- James DalySavannah$12K
- Romy HoqueAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.